Loading...
Market
Percentage change in Novavax stock price by January 31, 2025?
2
Resolution / Starting Odds
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Decrease by more than 20% • 25%
NASDAQ stock price data
Story
Novavax (NVAX) Shares Plunge 20% as FDA Halts Phase 3 COVID-Flu Vaccine Trials Over Motor Neuropathy
Oct 16, 2024, 02:17 PM
Novavax (NASDAQ: NVAX) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Investigational New Drug (IND) applications for both its COVID-19-influenza combination vaccine and its stand-alone influenza vaccine candidates in Phase 3 trials. The hold is due to safety concerns following a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a trial participant. Following the news on Wednesday, shares of Novavax plunged by up to 20%, with the stock dropping as much as 18.7% during trading.
View original story
Similar markets
Increases by more than 20% • 25%
Increases by 10% to 20% • 25%
Stays within +/- 10% • 25%
Decreases by more than 10% • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by 0-10% • 25%
Increase by more than 10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by 10% or more • 25%
Increases by 10% or more • 25%
Decreases by 10% or more • 25%
Remains within 10% of current value • 25%
Other outcome • 25%